Zhiwei Hu

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 11

Top Venues

Cells

Antibodies (Basel, Switzerland)

Cancers

Scientific reports

Yale University School of Medicine

Central South University Xiangya School of Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Yale University School of Medicine Dec 01 2012

United States

Visiting Associate Professor :: Obstetrics, Gynecology & Reproductive Sciences

The Ohio State University Wexner Medical Center Nov 01 2012

United States

Associate Professor :: Surgery

Yale University School of Medicine Oct 01 2007 - Oct 30 2012

United States

Research Scientist (Research Associate Professor) :: Obstetrics, Gynecology and Reproductive Sciences

Yale University School of Medicine Jul 01 2002 - Sep 30 2007

United States

Research Scientist (Research Associate Professor) :: Molecular Biophysics and Biochemistry

Yale University School of Medicine Apr 01 2000 - Jun 30 2002

United States

Associate Research Scientist (Research Assistant Professor) :: Molecular Biophysics and Biochemistry

Education History

Central South University Xiangya School of Medicine Sep 01 1994 - Jun 30 1997

China

PHD :: Cancer Research Institute

Medical College of Nanchang University Sep 01 1991 - Jun 30 1994

China

MSC :: Pathophysiology

Publications

Lingbin Meng, Katharine A Collier, Peng Wang, Zihai Li, Paul Monk, Amir Mortazavi, Zhiwei Hu, Daniel J Spakowicz, Linghua Zheng, Yuanquan Yang
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma. Cells 13 (1) (2023)
Lingbin Meng, Katharine A Collier, Peng Wang, Zihai Li, Paul Monk, Amir Mortazavi, Zhiwei Hu, Daniel J Spakowicz, Linghua Zheng, Yuanquan Yang
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma. Cells 13 (1) (2023)
Lingbin Meng, Katharine A Collier, Peng Wang, Zihai Li, Paul Monk, Amir Mortazavi, Zhiwei Hu, Daniel J Spakowicz, Linghua Zheng, Yuanquan Yang
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma. Cells 13 (1) (2023)
Lingbin Meng, Katharine A Collier, Peng Wang, Zihai Li, Paul Monk, Amir Mortazavi, Zhiwei Hu, Daniel J Spakowicz, Linghua Zheng, Yuanquan Yang
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma. Cells 13 (1) (2023)
Lingbin Meng, Katharine A Collier, Peng Wang, Zihai Li, Paul Monk, Amir Mortazavi, Zhiwei Hu, Daniel J Spakowicz, Linghua Zheng, Yuanquan Yang
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma. Cells 13 (1) (2023)
Lingbin Meng, Katharine A Collier, Peng Wang, Zihai Li, Paul Monk, Amir Mortazavi, Zhiwei Hu, Daniel J Spakowicz, Linghua Zheng, Yuanquan Yang
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma. Cells 13 (1) (2023)
Hongji Zhang, Yu Wang, Amblessed E Onuma, Jiayi He, Han Wang, Yujia Xia, Rhea Lal, Xiang Cheng, Gyulnara Kasumova, Zhiwei Hu, Meihong Deng, Joal D Beane, Alex C Kim, Hai Huang, Allan Tsung
Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer. Cancers 13 (21) (2021)
Zhiwei Hu
Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. Scientific reports 10 (1) (2020)
Salvador Gomez, Allan Tsung, Zhiwei Hu
Current Targets and Bioconjugation Strategies in Photodynamic Diagnosis and Therapy of Cancer. Molecules (Basel, Switzerland) 25 (21) (2020)
Zhiwei Hu
Therapeutic Antibody-Like Immunoconjugates against Tissue Factor with the Potential to Treat Angiogenesis-Dependent as Well as Macrophage-Associated Human Diseases. Antibodies (Basel, Switzerland) 7 (1) (2018)
Zhiwei Hu, Jijun Cheng, Jie Xu, Wolfram Ruf, Charles J Lockwood
Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy. Angiogenesis 20 (1) (2016)

Zhiwei Hu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Zhiwei Hu